Does Wegovy Cause Thyroid Cancer?
No, Wegovy (semaglutide) does not cause thyroid cancer in humans, based on clinical trial data and post-marketing surveillance. However, it carries a boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), due to findings in rodents. Human evidence shows no confirmed causal link.[1][2]
Why the Thyroid Cancer Warning on the Label?
The FDA requires a boxed warning because rodent studies showed dose-dependent thyroid C-cell tumors with semaglutide. These tumors occurred at exposures similar to human doses. No such effect appeared in human trials or monkey studies, where thyroid C-cells differ biologically from rodents.[1][3]
Evidence from Clinical Trials and Real-World Data
In Wegovy's approval trials (STEP program, over 4,500 patients), no cases of MTC or thyroid cancer were reported. Long-term data from SUSTAIN trials (up to 2 years) also showed no signal. Post-approval, VAERS and global surveillance report rare thyroid events, but none proven causally linked to Wegovy. A 2023 analysis of over 1 million GLP-1 users found no increased thyroid cancer risk.[2][4]
Who Should Avoid Wegovy Due to Thyroid Risks?
Patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) must not use it—contraindicated due to genetic predisposition amplifying any theoretical risk. Monitor for symptoms like neck mass or hoarseness; discontinue if suspected.[1]
How Does This Compare to Ozempic or Other GLP-1 Drugs?
Same active ingredient as Ozempic, so identical warning. All GLP-1 agonists (e.g., Mounjaro, Saxenda) carry similar rodent-based warnings, but no class-wide human causation. Tirzepatide (Mounjaro) showed no thyroid tumors in rodents at clinical exposures.[3][5]
Ongoing Studies and Patent Insights
Phase 4 trials track long-term thyroid safety; no interim signals of harm. Semaglutide patents expire around 2032 in the US, with generics eyed post-exclusivity—thyroid concerns unlikely to delay approvals absent new data. Check DrugPatentWatch.com for expiry details.[6]
Sources
[1]: Wegovy Prescribing Information (Novo Nordisk)
[2]: FDA Drug Safety Communication on GLP-1s
[3]: NEJM: Semaglutide Cardiovascular Outcomes Trial
[4]: JAMA Network Open: GLP-1s and Cancer Risk Meta-Analysis (2023)
[5]: Mounjaro Prescribing Information (Eli Lilly)
[6]: DrugPatentWatch: Wegovy Patents